Tuesday, July 6, 2021

NICE backs restricted use of Ondexxya

NHS cost regulators have backed funding for Alexion’s Ondexxya (andexanet alfa) to reverse anticoagulation of the direct factor Xa (FXa) inhibitors apixaban or rivaroxaban in adults who experience a life-threatening or uncontrolled bleed in the gastrointestinal (GI) tract.

Until now, there has been no licensed therapy to reverse FXa-associated major bleeds when treated with apixaban or rivaroxaban, which are increasingly used for the prevention and treatment of thrombotic events, such as deep vein thrombosis and pulmonary embolism, or if a patient is at high risk of a stroke due to an irregular heart rate (atrial fibrillation).

FXa inhibitors stop the blood from clotting normally to help prevent unwanted clots from forming, but in doing so can also raise the risk of major and potentially life-threatening bleeds.

Studies have shown that Ondexxya can reverse the anticoagulant effect of apixaban or rivaroxaban within two minutes of administration.

However, in a final appraisal document (FAD), NICE highlighted limitations in the clinical evidence and concluded that the drug is likely to be a cost effective use of resources for gastrointestinal bleeding, but not for intracranial haemorrhage (ICH) or bleeds in other part of the body.

Alexion said it is collecting additional data for the use of Ondexxya in ICH bleeds and is committed to continuing to work closely with NICE, NHS England and all other stakeholders “to find a sustainable path forward to secure future funded access” to the drug for those patients in England who experience an ICH bleed and “could benefit from this first-in-class therapy”.

Source link

Stay Connected


Latest Articles

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...

Telangana caps Covid treatment charges in private hospitals

Hyderabad: The government of Telangana on Wednesday issued orders fixing treatment and investigation charges for Covid-19 in private hospitals.The state government, which had capped...